Skip to main content
SpringerLink
Log in

Chemical Component Separation Using Botulinum Toxin

  • Chapter
  • First Online:
Hernia Surgery

Abstract

“Chemical Component Separation” is a novel concept that involves the application botulinum neurotoxin A (BoNT-A), a potent muscle-paralyzing agent, to achieve muscle relaxation of the abdominal wall muscles as an aid in the surgical repair of complex ventral and incisional hernias and for facilitating closure of midline abdominal wall defects. However, the number of clinical studies is limited and the experience with the application of BoNT-A in the field abdominal wall surgery is still preliminary. Achievement of tension- and retraction-free conditions in complex abdominal wall reconstruction is the main objective taking advantage of BoNT-A-related paralysis of abdominal wall muscles following injections in selected points on both sides of the abdomen. Better postoperative pain control and reduction of opioid analgesia are related to the antinociceptive effects of BoNT-A. Recommended techniques to guide botulinum toxin injection include electromyography, electric nerve stimulation, ultrasound, and anatomical localization. Formulations are not interchangeable. Potential applications of BoNT-A in adult patients may include complex and non-complex midline incisional hernias with loss of domain, open abdomen, or reconstructions when the abdominal wall is intact, with or without preoperative progressive pneumoperitoneum. Further studies, preferably randomized-controlled designs are necessary to clarify a number of relevant clinical questions, including patient’s eligibility, dosing of the different botulinum A formulations, optimal administration technique, or benefits of potential association with other procedures. The evidence available at the present time is still weak and a clear role of BoNT-A in abdominal wall surgery remains to be defined.

“The accuracy not necessarily leads to truth, speculation is not incompatible with the rigor”

Thomas S. Kuhn

The Structure of Scientific Revolutions, 1962

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312:71–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Glasser SP, Duval S. Meta-analysis, evidence-based medicine, and clinical guidelines. In: Glasser SP, editor. Essentials of clinical research. 2nd ed. Berlin: Springer International; 2014. p. 203–32.

    Google Scholar 

  3. López-Cano M. Evidence-based surgery and incisional hernia. Rev Hispanoamer Hernia. 2013;1:18–26.

    Article  Google Scholar 

  4. Zielinski MD, Goussous N, Schiller HJ, Jenkins D. Chemical component separation with botulinum toxin A: a novel technique to improve primary fascial closure rates of the open abdomen. Hernia. 2013;17:101–7.

    Article  CAS  PubMed  Google Scholar 

  5. Aoki KR. Botulinum toxin: a successful therapeutic protein. Curr Med Chem. 2004;11:3085–92.

    Article  CAS  PubMed  Google Scholar 

  6. Ibarra-Hurtado TR, Nuño-Guzmán CM, Miranda-Díaz AG, Troyo-Sanromán R, Navarro-Ibarra R, Bravo-Cuéllar L. Effect of botulinum toxin type A in lateral abdominal wall muscles thickness and length of patients with midline incisional hernia secondary to open abdomen management. Hernia. 2014;18:647–52.

    Google Scholar 

  7. Ibarra-Hurtado TR, Nuño-Guzmán CM, Echeagaray-Herrera JE, Robles-Vélez E, de Jesús González-Jaime J. Use of botulinum toxin type A before abdominal wall hernia reconstruction. World J Surg. 2009;33:2553–6.

    Article  PubMed  Google Scholar 

  8. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004;19 Suppl 8:S2–6.

    Article  PubMed  Google Scholar 

  9. Bigalke H, Dressler D, Jankovic J. Basic and therapeutic aspects of neurotonins. Mov Disord. 2004;19 Suppl 8:S1.

    Article  Google Scholar 

  10. Chaddock JA, Purkiss JR, Alexander FC, Doward S, Fooks SJ, Friis LM, et al. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov Disord. 2004;19 Suppl 8:S42–7.

    Article  PubMed  Google Scholar 

  11. Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55:8–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1–9.

    Article  PubMed  Google Scholar 

  13. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008;121:413–22.

    Article  Google Scholar 

  14. Hoffman RO, Helveston EM. Botulinum in the treatment of adult motility disorders. Int Ophthalmol Clin. 1986;26:241–50.

    Article  CAS  PubMed  Google Scholar 

  15. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8 Suppl 5:21–9.

    Article  PubMed  Google Scholar 

  16. U.S. Food and Drug Administration.

    Google Scholar 

  17. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13:10–9.

    Article  PubMed  Google Scholar 

  18. Kranz G, Paul A, Voller B, Posch M, Windischberger C, Auff E, Sycha T. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. Br J Dermatol. 2011;164:176–81.

    Article  CAS  PubMed  Google Scholar 

  19. Esquenazi A, Mayer N. Botulinum toxin for the management of muscle overactivity and spasticity after stroke. Curr Atheroscler Rep. 2001;3:295–8.

    Article  CAS  PubMed  Google Scholar 

  20. Pathak MS, Nguyen HT, Graham HK, Moore AP. Management of spasticity in adults: practical application of botulinum toxin. Eur J Neurol. 2006;13 Suppl 1:42–50.

    Article  PubMed  Google Scholar 

  21. Bonaparte JP, Ellis D, Quinn JG, Ansari MT, Rabski J, Kilty SJ. A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses. Syst Rev. 2013;2:40.

    Google Scholar 

  22. Borodic G. Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides. Ophthal Plast Reconstr Surg. 2006;22:239–40.

    Article  PubMed  Google Scholar 

  23. Dressler D, Wohlfahrt K, Meyer-Rogge E, Wiest L, Bigalke H. Antibody-induced failure of botulinum toxin: a therapy in cosmetic indications. Dermatol Surg. 2010;36 Suppl 4:2182–7.

    Article  CAS  PubMed  Google Scholar 

  24. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Therapy with botulinum toxin. J Neurol Neurosurg Psychiatry. 2002;72:459–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Panjwani N, O’Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J. 2008;1:153–66.

    Article  Google Scholar 

  26. Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord. 2009;24:231–6.

    Article  PubMed  Google Scholar 

  27. Jandhyala R. Relative potency of incobotulinum toxin A vs onabotulinum toxin A: a meta-analysis of key evidence. J Drugs Dermatol. 2012;11:731–6.

    CAS  PubMed  Google Scholar 

  28. Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013;4:10.

    Google Scholar 

  29. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord. 1994;9:31–9.

    Article  CAS  PubMed  Google Scholar 

  30. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol. 2004;140:1351–4.

    Article  CAS  PubMed  Google Scholar 

  31. Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol. 2008;7:50–4.

    Article  PubMed  Google Scholar 

  32. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62:198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Glanzman RL, Gelb DJ, Drury I, Bromberg MB, Truong DD. Brachial plexopathy after botulinum toxin injections. Neurology. 1990;40:1143.

    Article  CAS  PubMed  Google Scholar 

  34. Schnider P, Brichta A, Schmied M, Auff E. Gallbladder dysfunction induced by botulinum A toxin. Lancet. 1993;342:811–2.

    Article  CAS  PubMed  Google Scholar 

  35. Latimer PR, Hodgkins PR, Vakalis BRE, Evans AR, Zaki GA. Necrotising fasciitis as a complication of botulinum toxin treatment. Eye. 1998;12:51–3.

    Article  PubMed  Google Scholar 

  36. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19 Suppl 8:S92–100.

    Article  PubMed  Google Scholar 

  37. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–7.

    Article  CAS  PubMed  Google Scholar 

  38. Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991;48:1253–6.

    Article  CAS  PubMed  Google Scholar 

  39. Sheean GL, Lees AJ. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. J Neurol Neurosurg Psychiatry. 1995;59:601–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Dressler D, Dirnberger G. Botulinum toxin therapy: risk factors for therapy failure. Mov Disord. 2000;15 Suppl 2:51.

    Google Scholar 

  41. Cakmak M, Caglayan F, Somuncu S, Leventoglu A, Ulusoy S, Akman H, et al. Effect of paralysis of the abdominal wall muscles by botulinum A toxin to intraabdominal pressure: an experimental study. J Pediatr Surg. 2006;4:821–5.

    Article  Google Scholar 

  42. Smoot D, Zielinski M, Jenkins D, Schiller H. Botox A injection for pain after laparoscopic ventral hernia: a case report. Pain Med. 2011;12:1121–3.

    Article  PubMed  Google Scholar 

  43. Zendejas B, Khasawneh MA, Srvantstyan B, Jenkins DH, Schiller HJ, Zielinski MD. Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg. 2013;37:2830–7.

    Article  PubMed  Google Scholar 

  44. Rosin D. Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg. 2013;37:2838.

    Google Scholar 

  45. Ibarra-Hurtado TR, Nuño-Guzmán CM. Comment to: chemical components separation with botulinum toxin A: a novel technique to improve primary fascial closure rates of the open abdomen by Zielinski et al. Hernia. 2013;17:109–10.

    Article  CAS  PubMed  Google Scholar 

  46. Harth K, Rosen M, Blatnik J, Schomisch S, Cash A, Soltanian H. Chemical myotomy with botulinum toxin for abdominal wall reconstruction: results of a porcine pilot study. Plast Reconstruct Surg. 2011;127 Suppl 5:S99.

    Article  Google Scholar 

  47. Chávez-Tostado KV, Cárdenas-Lailsonb LE, Pérez-Trigosb H. Results of preoperative application of botulinum toxin type A in treatment of giant incisional hernias. Rev Hispanoam Hernia. 2014;2:145–51.

    Article  Google Scholar 

  48. Ibarra Hurtado TR, Negrete Ramosa GI, Preciado Hernández F, Nuño Guzmán CM, Tapia Alcalá E, Bravo CL. Botulinum toxin type A as an adjuvant in bilateral inguinoscrotal hernia with loss of domain. First case report and literature review. Rev Hispanoam Hernia. 2014;2:139–44.

    Article  Google Scholar 

  49. López-Cano M, Pereira JA, Armengol-Carrasco M. “Acute postoperative open abdominal wall”: Nosological concept and treatment implications. World J Gastrointest Surg. 2013;5:314–20.

    Article  PubMed  PubMed Central  Google Scholar 

  50. ClinicalTrials.gov [NCT01495962]. https://clinicaltrials.gov/ct2/show/study/NCT01495962?term=botulinum+toxin+and+abdominal+wall+reconstruction&rank=1.

  51. Slater NJ, Montgomery A, Berrevoet F, Carbonell AM, Chang A, Franklin M, et al. Criteria for definition of a complex abdominal wall hernia. Hernia. 2014;18:7–17.

    Article  CAS  PubMed  Google Scholar 

  52. Petersson U, Acosta S, Björck M. Vacuum-assisted wound closure and mesh-mediated fascial traction—a novel technique for late closure of the open abdomen. World J Surg. 2007;31:2133–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The authors thank Marta Pulido, MD, for editing the manuscript and editorial assistance.

Author information

Authors and Affiliations

  1. Abdominal Wall Surgery Unit, General and Digestive Surgery, Hospital Universitario Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

    Manuel López-Cano M.D.

  2. Department of Surgery, Hospital Universitario Vall d’Hebron, Barcelona, Spain

    Manuel Armengol-Carrasco M.D.

Authors
  1. Manuel López-Cano M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel Armengol-Carrasco M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel López-Cano M.D. .

Editor information

Editors and Affiliations

  1. Case Comprehensive Hernia Center, University Hospitals Case Medical Center, Cleveland, Ohio, USA

    Yuri W. Novitsky

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Botulinum neurotoxin injection before VHR, by Lopez-Cano (M4V 112,938 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

López-Cano, M., Armengol-Carrasco, M. (2016). Chemical Component Separation Using Botulinum Toxin. In: Novitsky, Y. (eds) Hernia Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-27470-6_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27470-6_41

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27468-3

  • Online ISBN: 978-3-319-27470-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation